| Research priorities | |
|---|---|
|
| |
| 4.1 | Define the optimal antithrombotic regimen (safety and efficacy) in patients with CLTI to reduce cardiovascular and limb-specific events. |
| 4.2 | Define treatment targets and optimal dosing for lipid-lowering agents in the CLTI population. |
| 4.3 | Identify biomarkers predictive of clinical events in the CLTI population that may serve as targets for therapy. |
| 4.4 | Identify effective smoking cessation strategies for patients with advanced PAD and CLTI. |
| 4.5 | Identify the type of analgesia that is most effective in patients with chronic pain secondary to CLTI. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.